Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71

Ritossa, 1996, Discovery of the heat shock response, Cell Stress Chaperones, 1, 97, 10.1379/1466-1268(1996)001<0097:DOTHSR>2.3.CO;2

Westerheide, 2005, Heat shock response modulators as therapeutic tools for the diseases of protein conformation, J Biol Chem, 280, 33097, 10.1074/jbc.R500010200

Wiech, 1992, Hsp90 chaperones protein folding in vitro, Nature, 358, 169, 10.1038/358169a0

Schneider, 1996, Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90, Proc Natl Acad Sci USA, 93, 14536, 10.1073/pnas.93.25.14536

Zhao, 2005, Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone, Cell, 120, 715, 10.1016/j.cell.2004.12.024

Neckers, 2002, Hsp90 inhibitors as novel cancer chemotherapeutic agents, Trends Mol Med, 8, S55, 10.1016/S1471-4914(02)02316-X

Russell, 2003, Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization, Clin Cancer Res, 37, 3749

Machida, 2003, Geldanamycin, an inhibitor of Hsp90, sensitizes human tumor cells to radiation, Int J Radiat Biol, 79, 973, 10.1080/09553000310001626135

Machida, 2005, Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldamamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis, Cancer Sci, 96, 911, 10.1111/j.1349-7006.2005.00125.x

Matsumoto, 2005, Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin, J Radiat Res, 46, 215, 10.1269/jrr.46.215

Noguchi, 2006, Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldamamycin, Biochem Biophys Res Commun, 351, 658, 10.1016/j.bbrc.2006.10.094

Solit, 2007, Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer, Clin Cancer Res, 13, 1775, 10.1158/1078-0432.CCR-06-1863

Taldone, 2008, Targeting Hsp90: small-molecule inhibitors and their clinical development, Curr Opin Pharmacol, 8, 370, 10.1016/j.coph.2008.06.015

Chiosis, 2008, Discovery and development of purine-scaffold Hsp90 inhibitors, Expert Opin Drug Discov, 3, 99, 10.1517/17460441.3.1.99

Caldas-Lopes, 2009, Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models, Proc Natl Acad Sci USA, 106, 8368, 10.1073/pnas.0903392106

Briones, 2010, Targeted therapy of BCL6-dependent diffuse large B-cell lymphoma by heat-shock protein 90 inhibition, Expert Rev Hematol, 3, 157, 10.1586/ehm.10.11

Breinig, 2009, Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma, Hepatology, 50, 102, 10.1002/hep.22912

Li, 2008, Homologous recombination in DNA repair and DNA damage tolerance, Cell Res, 18, 99, 10.1038/cr.2008.1

Kuribayashi, 2010, Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation, Int J Mol Med, 25, 25

Bee, 2013, The efficiency of homologous recombination and non-homologous end joining systems in repairing double-strand breaks during cell cycle progression, PloS One, 8, e69061, 10.1371/journal.pone.0069061

Bull, 2004, Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin, Clin Cancer Res, 10, 8077, 10.1158/1078-0432.CCR-04-1212

Bisht, 2003, Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity, Cancer Res, 63, 8984

Koll, 2008, HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair, Mol Cancer Ther, 7, 1985, 10.1158/1535-7163.MCT-07-2104

Stingl, 2010, Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction, Br J Cancer, 102, 1578, 10.1038/sj.bjc.6605683

Kubota, 2012, Hsp90 inhibitors are promising radiosensitizers for radiotherapy, Thermal Med, 28, 53, 10.3191/thermalmed.28.53

Sharp, 2006, Inhibitors of the HSP90 molecular chaperone: current status, Adv Cancer Res, 95, 323, 10.1016/S0065-230X(06)95009-X

Chiosis, 2001, A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells, Chem Biol, 8, 289, 10.1016/S1074-5521(01)00015-1

Chiosis, 2006, Discovery and development of purine-scaffold Hsp90 inhibitors, Curr Top Med Chem, 6, 1183, 10.2174/156802606777812013

Chiosis, 2006, Emerging Hsp90 inhibitors: from discovery to clinic, Anticancer Agents Med Chem, 6, 1, 10.2174/187152006774755483

Zaidi, 2012, The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage, PLos One, 7, e35436, 10.1371/journal.pone.0035436